Logistic regression analysis for predictors of response according to PET4 criteria in rituximab-treated DLBCL patients (n = 97)
. | OR . | 95% CI . | P . |
---|---|---|---|
Univariate analysis | |||
AUC1 ≥9400 mg × h per liter | 3.47 | 1.52-8.21 | .004 |
TMTV0, cm3 (×10−2) | 0.91 | 0.82-0.98 | .033 |
IPI (3-4) | 0.36 | 0.15-0.82 | .017 |
Chemotherapy (CHOP) | 0.95 | 0.42-2.14 | .90 |
Male | 0.56 | 0.24-1.27 | .17 |
Age, y | 1.04 | 1.003-1.08 | .036 |
Final model* | |||
AUC1 ≥9400 mg × h per liter | 5.56 | 2.19-15.62 | .0006 |
Age, y | 1.06 | 1.02-1.10 | .004 |
. | OR . | 95% CI . | P . |
---|---|---|---|
Univariate analysis | |||
AUC1 ≥9400 mg × h per liter | 3.47 | 1.52-8.21 | .004 |
TMTV0, cm3 (×10−2) | 0.91 | 0.82-0.98 | .033 |
IPI (3-4) | 0.36 | 0.15-0.82 | .017 |
Chemotherapy (CHOP) | 0.95 | 0.42-2.14 | .90 |
Male | 0.56 | 0.24-1.27 | .17 |
Age, y | 1.04 | 1.003-1.08 | .036 |
Final model* | |||
AUC1 ≥9400 mg × h per liter | 5.56 | 2.19-15.62 | .0006 |
Age, y | 1.06 | 1.02-1.10 | .004 |
OR, odds ratio.
Final model includes significant covariates in the multivariate analysis.